Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2020 Apr 27;159(4):1623–1624.e3. doi: 10.1053/j.gastro.2020.04.051

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the AGA Institute.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Supplementary Figure 1 — Association between (A) steroids, (B) mesalamines (5-ASA), (C) thiopurines, and (D) anti-tumor necrosis factor (TNF)-α agents and mucosal ACE2 messenger RNA (mRNA) expression, angiotensin-converting enzyme 2 (ACE2) activity, and immunohistochemical (IHC) staining intensity in colonoscopic biopsies in patients with inflammatory bowel disease (IBD). No statistically significant differences were noted.

Supplementary Figure 1 — Association between (A) steroids, (B) mesalamines (5-ASA), (C) thiopurines, and (D) anti-tumor necrosis factor (TNF)-α agents and mucosal ACE2 messenger RNA (mRNA) expression, angiotensin-converting enzyme 2 (ACE2) activity, and immunohistochemical (IHC) staining intensity in colonoscopic biopsies in patients with inflammatory bowel disease (IBD). No statistically significant differences were noted.